Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. [electronic resource]
Producer: 20100804Description: 3491-7 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Biliary Tract Neoplasms -- drug therapy
- Cholangiocarcinoma -- drug therapy
- Drug Administration Schedule
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride
- Female
- Humans
- Male
- Middle Aged
- Quinazolines -- administration & dosage
- Vascular Endothelial Growth Factor A -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.